MNG91
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.418
- G2M_CHECKPOINT+0.378
- GLYCOLYSIS+0.291
- MYC_TARGETS_V2+0.284
- TNFA_SIGNALING_VIA_NFKB+0.224
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.222
- ESTROGEN_RESPONSE_LATE+0.220
- MTORC1_SIGNALING+0.216
- SPERMATOGENESIS+0.179
- INTERFERON_GAMMA_RESPONSE+0.174
Top 10 suppressed
- PROTEIN_SECRETION-0.434
- TGF_BETA_SIGNALING-0.347
- UNFOLDED_PROTEIN_RESPONSE-0.269
- UV_RESPONSE_DN-0.261
- HEME_METABOLISM-0.245
- NOTCH_SIGNALING-0.209
- MYC_TARGETS_V1-0.193
- WNT_BETA_CATENIN_SIGNALING-0.190
- ANDROGEN_RESPONSE-0.176
- DNA_REPAIR-0.146
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG161 | — | — | 0.743 |
| 2 | X55c46455.46e3.40c2.ba37.333e25431e91 | — | cohortA4 | 0.694 |
| 3 | MNG158 | — | — | 0.689 |
| 4 | SRR26320078 | — | — | 0.640 |
| 5 | MNG1266 | — | — | 0.639 |
| 6 | MNG774 | — | — | 0.629 |
| 7 | MNG192 | — | — | 0.627 |
| 8 | f02aa649-f382-4f91-9a51-ce73199f8fbc | — | — | 0.616 |
| 9 | TCGA-NC-A5HM-01A-12R-A26W-07 | — | cohortSQ1 | 0.615 |
| 10 | SRR12202407 | — | — | 0.613 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.418 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.378 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.291 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.284 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.224 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.222 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.216 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.179 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.174 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.134 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.118 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.114 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.103 | Idelalisib | — uncovered |
| HYPOXIA | 0.096 | Idelalisib | — uncovered |
| APOPTOSIS | 0.095 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.086 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.082 | Inavolisib | — uncovered |